Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Steve Olsen

Showing results (11-20 of 18) with videos related to

Pageof 2
Sort By:
You have reached the last page of results.This site can display upto 18 results.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|February 28, 2016
Relationship between Tumor Biomarkers and Efficacy in EMILIA, a Phase III Study of Trastuzumab Emtansine in HER2-Positive Metastatic Breast CancerJosé Baselga, Gail D Lewis Phillips, Sunil Verma, et al.
Cancer|April 7, 2021
High concordance of actionable genomic alterations identified between circulating tumor DNA-based and tissue-based next-generation sequencing testing in advanced non-small cell lung cancer: The Korean Lung Liquid Versus Invasive Biopsy ProgramSehhoon Park, Steve Olsen, Bo Mi Ku, et al.
Frontiers in Oncology|October 7, 2024
Utilization of tissue-free minimal residual disease testing in colorectal cancer patients from Asia and Middle EastSuyog Jain, Shaheenah Dawood, Viraj Lavingia, et al.
Cancer Medicine|April 19, 2022
Longitudinal monitoring by next-generation sequencing of plasma cell-free DNA in ALK rearranged NSCLC patients treated with ALK tyrosine kinase inhibitorsMinsuk Kwon, Bo Mi Ku, Steve Olsen, et al.
Journal of Clinical Medicine|May 14, 2022
<i>FGFR</i> Fusions as an Acquired Resistance Mechanism Following Treatment with Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors (EGFR TKIs) and a Suggested Novel Target in Advanced Non-Small Cell Lung Cancer (aNSCLC)Ari Raphael, Elizabeth Dudnik, Dov Hershkovitz, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|November 6, 2014
Potential mechanisms for thrombocytopenia development with trastuzumab emtansine (T-DM1)Hirdesh Uppal, Estelle Doudement, Kaushiki Mahapatra, et al.
European Journal of Cancer (Oxford, England : 1990)|September 18, 2023
Upfront liquid next-generation sequencing in treatment-naïve advanced non-small cell lung cancer patients: A prospective randomised study in the Taiwanese health systemChing-Yao Yang, Jin-Yuan Shih, Wei-Yu Liao, et al.
Nature Medicine|November 12, 2021
Circulating tumor DNA-guided treatment with pertuzumab plus trastuzumab for HER2-amplified metastatic colorectal cancer: a phase 2 trialYoshiaki Nakamura, Wataru Okamoto, Takeshi Kato, et al.
Pageof 2

Showing results (11-20 of 18) with videos related to

Sort By:
Pageof 2
You have reached the last page of results.This site can display upto 18 results.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|February 28, 2016
Relationship between Tumor Biomarkers and Efficacy in EMILIA, a Phase III Study of Trastuzumab Emtansine in HER2-Positive Metastatic Breast CancerJosé Baselga, Gail D Lewis Phillips, Sunil Verma, et al.
Cancer|April 7, 2021
High concordance of actionable genomic alterations identified between circulating tumor DNA-based and tissue-based next-generation sequencing testing in advanced non-small cell lung cancer: The Korean Lung Liquid Versus Invasive Biopsy ProgramSehhoon Park, Steve Olsen, Bo Mi Ku, et al.
Frontiers in Oncology|October 7, 2024
Utilization of tissue-free minimal residual disease testing in colorectal cancer patients from Asia and Middle EastSuyog Jain, Shaheenah Dawood, Viraj Lavingia, et al.
Cancer Medicine|April 19, 2022
Longitudinal monitoring by next-generation sequencing of plasma cell-free DNA in ALK rearranged NSCLC patients treated with ALK tyrosine kinase inhibitorsMinsuk Kwon, Bo Mi Ku, Steve Olsen, et al.
Journal of Clinical Medicine|May 14, 2022
<i>FGFR</i> Fusions as an Acquired Resistance Mechanism Following Treatment with Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors (EGFR TKIs) and a Suggested Novel Target in Advanced Non-Small Cell Lung Cancer (aNSCLC)Ari Raphael, Elizabeth Dudnik, Dov Hershkovitz, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|November 6, 2014
Potential mechanisms for thrombocytopenia development with trastuzumab emtansine (T-DM1)Hirdesh Uppal, Estelle Doudement, Kaushiki Mahapatra, et al.
European Journal of Cancer (Oxford, England : 1990)|September 18, 2023
Upfront liquid next-generation sequencing in treatment-naïve advanced non-small cell lung cancer patients: A prospective randomised study in the Taiwanese health systemChing-Yao Yang, Jin-Yuan Shih, Wei-Yu Liao, et al.
Nature Medicine|November 12, 2021
Circulating tumor DNA-guided treatment with pertuzumab plus trastuzumab for HER2-amplified metastatic colorectal cancer: a phase 2 trialYoshiaki Nakamura, Wataru Okamoto, Takeshi Kato, et al.
Pageof 2